LDS 73/LW1

Reactivity: Anti-Glutathione S-Transferase subunit YC2, 96050401

• UNSPSC Code: 41106514
• Biological source: Mouse x Mouse Hybridoma
• Isotype: IgG2a
• Technique(s): cell culture | mammalian: suitable
• Myeloma: NS0
• Reactivity: Anti-Glutathione S-Transferase subunit YC2

Eigenschaften

• biological source: Mouse x Mouse Hybridoma
• ImmunoDon: MF1 x BALB/c F mouse spleen cells
• Myeloma: NS0
• Reactivity: Anti-Glutathione S-Transferase subunit YC2
• technique(s): cell culture | mammalian: suitable
• isotype: IgG2a
• shipped in: dry ice
• storage temp.: −196°C

Beschreibung

Immunogen

Rat glutathione S-transferase subunit YC2

Application

Immunohistochemistry, Western blotting, ELISA assays

Biochem/physiol Actions

Mouse NS0 x Mouse (MF1xBALB/c F) spleen

The hybridoma cell line LDS 73/LW1 was produced by fusing NS0 myeloma cells with spleen cells from an MF1 x BALB/c mouse immunised with rat glutathione S-transferase subunit YC2. The cell line, also known as LW1, secretes antibodies that distinguish between subunit YC2 and YC1.

Preparation Note

Maintain cultures between 3-9x100,000 cells/ml; 5% CO₂; 37°C

RPMI 1640 or DMEM + 2mM glutamine + 10% Foetal Bovine Serum (FBS)

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by [email protected] to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.